Primary Central Nervous System Lymphoma - 27 Studies Found
| Active, not recruiting |
: Cranial Radiotherapy or Intensive Chemotherapy With Hematopoietic Stem Cell Rescue for Primary Central Nervous System Lymphoma in Young Patients : Primary Central Nervous System Lymphoma : 2009-03-16 :
|
| Recruiting |
: Maintenance Treatment Versus Observation in Elderly Patients With PCNS Lymphoma : Primary Central Nervous System Lymphoma : 2014-12-05 : Drug: Rituximab, Methotrexate, Temozolomide Seven monthly R-MT cycles including high dose MTX (3.5g/m2, |
| Recruiting |
: Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL) :
|
| Recruiting |
: Prospective Neurobehavioral Outcomes Follow-up in Primary CNS Lymphoma Patients Treated With Cranial Radiotherapy Combined With or Without MTX-based Chemotherapy According to the Multidisciplinary Treatment Guidelines Implemented at a Single Institute : Primary Central Nervous System Lymphoma : 2015-12-09 : Radiation: Standard treatment protocol with combined chemoradiation |
| Enrolling by invitation |
: Treatment of PCNSL With R-IDARAM and Intrathecal Immunochemotherapy : Primary Central Nervous System Lymphoma : 2014-04-23 : Drug: R-IDARAM plus intrathecal chemotherapy R-IDARAM comprised of rituximab 375 mg/m2 (day 1), idarubic |
| Recruiting |
: Therapeutic Effects of R-IDARAM and Intrathecal Immunochemotherapy on Elderly Patients With PCNSL : Primary Central Nervous System Lymphoma : 2016-07-14 : Drug: R-IDARAM plus intrathecal chemotherapy R-IDARAM comprised of rituximab 375 mg/m2 (day 1), idarubic |
| Terminated |
: Study of High-Dose Rituximab With Temozolomide as Treatment for Primary Central Nervous System (CNS) Lymphoma : Primary Central Nervous System Lymphoma : 2014-04-10 : Drug: Rituximab plus Temozolomide Treatment cycles will be repeated every 14 days (2 weeks) for the lead |
| Completed |
: Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL) :
: Drug: Buparlisib (BKM120) Buparlisib 100 mg once daily. |
| Recruiting |
: Treatment of Primary CNS Lymphoma : Primary CNS Lymphoma (PCNSL) : 2013-10-08 :
|
| Recruiting |
: Temsirolimus in Recurrent Primary Central Nervous System (CNS) Lymphoma : Recurrent or Refractory Primary CNS Lymphoma : 2009-07-20 : Drug: temsirolimus Weekly infusion of 25mg Temsirolimus (first 3 patients) or 75mg Temsirolimus (all oth |